Influenza News and Research

Latest Influenza News and Research

BioCryst receives $1.1 million in grants under QTDP program

BioCryst Pharmaceuticals, Inc. today announced that the Company had been awarded $1.1 million in grants under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the Company's clinical programs for peramivir, BCX4208 and forodesine, as well as the pre-clinical BCX4161 kallikrein inhibitor and JAK inhibitor programs.

3 Nov 2010

Inviragen receives two grants to develop dengue and chikungunya vaccines

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, announced today that it has received two grants totaling $488,958 through the United States government's Qualifying Therapeutic Discovery Project Program.

3 Nov 2010

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

For patients with the most common form of hepatitis C being treated for the first time, the addition of an investigational hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy markedly improved their sustained viral response (SVR or viral cure) rate.

3 Nov 2010

PPACA program provides $733,438 grant to Inovio

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has received a $733,438 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA).

2 Nov 2010

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

NanoViricides, Inc. reported today that its FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu treated animals.

1 Nov 2010

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway.

1 Nov 2010

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).

1 Nov 2010

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.

1 Nov 2010

Child Life Program organizes Halloween celebration for children undergoing treatment

Once a year cartoon characters, fairy princesses and action heroes gather at St. Jude Children's Research Hospital as hundreds of employees work together to turn the hospital into a giant trick-or-treat trail for children battling cancer and other catastrophic diseases. The event spans buildings and floors throughout the campus in Memphis, Tenn.

1 Nov 2010

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.

1 Nov 2010

Rite Aid to host flu shot clinics at nationwide pharmacies

With the holidays getting closer, Rite Aid is reminding people to get a flu shot so that the only thing they are spreading this season is good cheer. According to The Centers for Disease Control and Prevention (CDC), it can take up to two weeks for flu shots to be effective and protect against the flu; those who get their flu shot now can help protect themselves by the time they sit down for Thanksgiving dinner.

30 Oct 2010

BioMedix receives ONC-ATCB 2011/2012 certification for TRAKnet Practice Management Software

BioMedix announced today that TRAKnet Practice Management Software 2.0 is 2011/2012 compliant and was certified as a Complete EHR on October 28th, 2010 by the Certification Commission for Health Information Technology (CCHIT®), an ONC-ATCB, in accordance with the applicable Eligible Provider certification criteria adopted by the Secretary of Health and Human Services.

30 Oct 2010

Progress update on Johnson & Johnson and Crucell's public offer

Pursuant to the provisions of Section 7 paragraph 1(a) of the Dutch Decree on Public Takeover Bids (Besluit Openbare Biedingen Wft) requiring a public announcement within four weeks following the announcement of an intended public offer to provide a status update, Johnson & Johnson (NYSE: JNJ) and Crucell N.V. provide the following joint update.

30 Oct 2010

Henry Schein third quarter net sales increases 14.1% to $1.9 billion

Henry Schein, Inc. the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended September 25, 2010.

29 Oct 2010

Phytonutrient Report says Americans do not consume enough fruits and vegetables

The majority of Americans report getting a cold or flu in the past year, and more than a third say they'll make lifestyle changes to prevent getting sick again this year. However, 40 percent of Americans don't plan to take what is arguably the easiest and tastiest step to help potentially prevent illness this cold and flu season eat more fruits and vegetables daily.

29 Oct 2010

ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc., today announced that treatment with its lead compound, Homspera®, improved the survival of animals vaccinated with an experimental melanoma vaccine.

29 Oct 2010

Research on sheep population could help explain variation in vaccine protection

Strong immunity may play a key role in determining long life, but may do so at the expense of reduced fertility, a Princeton University study has concluded.

29 Oct 2010

New nationwide initiative to conduct research on human immune system

A new nationwide research initiative has been launched to define changes in the human immune system's response to infection and vaccination using human rather than animal models, which could lead to better vaccines and other treatments. Baylor Research Institute (BRI), along with five other U.S.-based Human Immune Phenotyping Centers, will receive a total of $100 million over five years to conduct the research.

28 Oct 2010

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

BioCryst Pharmaceuticals, Inc. announced financial results for the third quarter and nine months ended September 30, 2010.

28 Oct 2010

AstraZeneca 2010 third quarter decreases 2% to $7,898 million

Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the third quarter declined by 2% at constant exchange rates (CER) to $7,898 million.

28 Oct 2010

Influenza News and Research

Latest Influenza News and Research

BioCryst receives $1.1 million in grants under QTDP program

Inviragen receives two grants to develop dengue and chikungunya vaccines

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

PPACA program provides $733,438 grant to Inovio

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Child Life Program organizes Halloween celebration for children undergoing treatment

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Rite Aid to host flu shot clinics at nationwide pharmacies

BioMedix receives ONC-ATCB 2011/2012 certification for TRAKnet Practice Management Software

Progress update on Johnson & Johnson and Crucell's public offer

Henry Schein third quarter net sales increases 14.1% to $1.9 billion

Phytonutrient Report says Americans do not consume enough fruits and vegetables

ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine

Research on sheep population could help explain variation in vaccine protection

New nationwide initiative to conduct research on human immune system

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

AstraZeneca 2010 third quarter decreases 2% to $7,898 million

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Influenza News and Research

Latest Influenza News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in